ARGX-110

DRUG3 trials

Sponsors

OncoVerity, Inc., argenx

Conditions

CancerLeukemia, Myeloid, AcuteMyelodysplastic SyndromesNeoplasms

Phase 1

A Study of ARGX-110 in Participants With Advanced Malignancies

CompletedNCT01813539

OncoVerity, Inc.Neoplasms

Start: 2013-02-27End: 2020-07-10Updated: 2023-08-09

A Study of ARGX-110 in Patients With Nasopharyngeal Carcinoma (NPC)

CompletedNCT02759250

Start: 2015-02-28End: 2018-06-30Updated: 2018-08-08

A Study of ARGX-110 in Combination With Azacytidine in Participants With Newly Diagnosed Acute Myeloid Leukemia (AML) or High Risk Myelodysplatic Syndrome (MDS)

CompletedNCT03030612

OncoVerity, Inc.Leukemia, Myeloid, Acute, Myelodysplastic Syndromes

Start: 2016-12-31End: 2022-08-31Updated: 2023-08-09

Related Papers

Trial in Progress: A Multicenter, Open Label, Randomized, Phase 2 Study of Venetoclax and Azacitidine Plus Cusatuzumab Versus Venetoclax and Azacitidine Alone in Newly Diagnosed AML Patients Who Are Not Candidates for Intensive Therapy

Blood2024-11-05

Targeting CD70 with cusatuzumab eliminates acute myeloid leukemia stem cells in patients treated with hypomethylating agents.

2020-06-29170 citations

CULMINATE: A phase II study of cusatuzumab + azacitidine in patients with newly diagnosed AML, ineligible for intensive chemotherapy.

Journal of Clinical Oncology2020-05-2010 citations

Targeting CD70 with Cusatuzumab Eliminates Acute Myeloid Leukemia Stem Cells in Humans

Blood2019-11-1311 citations

Argx-110 Targeting CD70, in Combination with Azacitidine, Shows Favorable Safety Profile and Promising Anti-Leukemia Activity in Newly Diagnosed AML Patients in an Ongoing Phase 1/2 Clinical Trial

Blood2018-11-2920 citations

Argx-110 for Treatment of CD70-Positive Advanced Cutaneous T-Cell Lymphoma in a Phase 1/2 Clinical Trial

Blood2018-11-297 citations

Clinical response observed in a phase I study in T cell lymphoma patients treated with anti-CD70 SIMPLE Antibody ARGX-110.

Journal of Clinical Oncology2016-05-204 citations

A phase I, first-in-human study of ARGX-110, a monoclonal antibody targeting CD70, a receptor involved in immune escape and tumor growth in patients with solid and hematologic malignancies.

Journal of Clinical Oncology2014-05-2011 citations

ARGX-110, a highly potent antibody targeting CD70, eliminates tumors via both enhanced ADCC and immune checkpoint blockade

mAbs2013-12-06100 citations